Compare Ishares Msci Spain ETF (EWP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Ishares Msci Spain ETF trades at $57.9 (market cap $2.31B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.1× Ishares Msci Spain ETF's market cap, and Ishares Msci Spain ETF is more actively traded (302,484 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWP | TVTX | |
|---|---|---|
Market Cap | $2.31B | $4.88B |
Volume | 302,484 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $67.52 |
52-Week Low | $48.95 | $26.79 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $58.34, up 0.52% on the day, with a bearish technical signal driven by moving averages. The stock faces resistance at $59 and support at $58. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights European market resilience amid ECB rate hikes and energy-driven inflation pressures.
Outlook is cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on Spain's equity valuation appeal, but risks include eurozone economic sentiment slippage and sustained inflation. Investors should await updated financials for fundamental assessment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
